Be kind, certify a class

In re KIND LLC “Healthy and All Natural” Litig., 2021 WL
1132147, Nos. 15md2645, 15mc2645 (S.D.N.Y. Mar. 24, 2021)

Plaintiffs sought class certification of their false
advertising claims based on the claims that KIND falsely advertised “All
Natural / Non-GMO,” “Non-GMO,” and “No Genetically Engineered Ingredients”;
KIND sought to exclude expert reports. Both were partially successful.

Plaintiffs allege that KIND products contain “a
conglomeration of chemically-synthesized and highly-processed ingredients,” that
“[t]esting … detected the presence of GMOs in at least some of the products,”
and that “approximately 90% of canola, 89% of corn, and 94% of soybeans grown
in the United States are genetically modified.” They brought NY, California,
and Florida claims.

Numerosity, adequacy, commonality, and typicality were
satisfied. “Even if a named Plaintiff did not see all of the label variants,
the typicality requirement would still be met. … The differences are slight and
all can be litigated in this action with the current class representatives.”

The class was also ascertainable. “While KIND labels varied,
all the labeling over the putative class period is allegedly deceptive. As
such, the possibility that a potential class member could join the litigation
without ever seeing the allegedly deceptive advertising cannot occur here.” Nor
was the lack of a receipt requirement fatal. “Imposing a receipt requirement
would severely constrict consumer class actions where most consumers do not
keep receipts because the purchase price is low and part of a minerun retail
transaction.”

The court thought that the three states’ laws were similar
enough on the key aspects to analyze predominance together, focusing on (1) the
deceptive act, (2) materiality, and (3) injury.

The court agreed that common questions about
deceptiveness/materiality predominated, given the extreme similarity in meaning
of the three label variants. None of the labels displayed “All Natural” on its
own, but always with “Non-GMO.” They could be proved true or false on a
classwide, as could materiality (which is an objective inquiry about reasonable
consumers under the governing laws). Nor was the fact that plaintiffs offered
various definitions of “All Natural” fatal; none of the definitions contradicted
each other. Finding commonality also served “important policy considerations”:

This consumer class action spins a
familiar tale. A large company produces similar products with different labels.
Should employing slightly different labels allow a company to escape liability?
… The labels on these products vary slightly but all are sufficiently similar
to draw potential customers to the KIND brand. Moreover, as every company does,
KIND refined its advertising strategy with the passage of time and market
research, resulting in gradual changes to its labeling. … If this Court
declined to certify the proposed classes, consumer-product companies would have
a roadmap to avoid class actions. And given the relative low cost of most
consumer products, those companies could avoid any liability for deceptive
labeling.

KIND also argued that the number of ingredients challenged
as non-natural defeated predominance. But, if a product contains (what a jury finds
to be) a single non-natural or GMO ingredient, the label is incorrect and plaintiffs
may be entitled to damages.

Plaintiffs were also prepared to have their expert quantify
the alleged price premium. A damages model for a false advertising case must
“isolate the premium due only to the allegedly misleading marketing statement.”
Plaintiffs’ expert proposed to use a hedonic regression and a conjoint analysis;
this could be workable despite the label variations. KIND’s argument to the
contrary assumed that different variations of the label would lead to different
premiums. First, a liability class could be certified even if damages weren’t
amenable to classwide proof. Second, all purchasers were exposed to allegedly
misleading advertising and therefore may have paid a premium. Third, the
differences among the labels were slight, making it unlikely that any
differences were significant.

The court also rejected KIND’s Daubert motion to
exclude the damages expert; he did all that was required at this stage: opine
what could be done to assess damages and that the data to do so were available.
A rebuttal expert from plaintiffs was, however, excluded as untimely.

Finally, superiority favored certification because a class
action was the best way to resolve this kind of dispute about a low-cost
problem, and it was already consolidated as MDL.

Plaintiffs were, however, not allowed to seek injunctive
relief under Rule 23(b)(2). Berni v. Barilla S.p.A., 964 F.3d 141 (2d Cir.
2020), held that past purchasers couldn’t maintain an injunctive class. They
weren’t definitely going to buy again, and they knew they’d been deceived
before, so they wouldn’t be fooled again. In the Second Circuit, inability to
rely on a continuing representation is not sufficient injury.

from Blogger https://ift.tt/3z6KyaP

Posted in Uncategorized | Tagged , , , | Leave a comment

patent misrepresentations to prospective dealer could be false advertising under Dastar/Lexmark

Three very similar
cases involving the same plaintiff.

Roof Maxx Technol., LLC
v. Holsinger,
2021 WL 3617153, No. 2:20-cv-03154
(S.D. Ohio Aug. 16, 2021)

Roof Maxx distributes “a
soy-based liquid product that is sprayed on asphalt shingle roofs to extend the
life of the shingles.” It enters into dealership agreements, often geographically
exclusive, around the country. It did so with Holsinger (Shingle Savers) and
included a noncompete. Shingle Savers ultimately terminated the agreement,
alleging misrepresentations by Roof Maxx; RM denied any misrepresentations and
sued, seeking declaratory judgment of the validity of the noncompete clause.

Shingle Savers
counterclaimed, alleging, among other things, false advertising under the
Lanham Act and violation of the Ohio Deceptive Trade Practices Act. It alleged
that RM enticed Holsinger to sign the agreement by falsely representing that
two generations of the product were patented, when it knew the patent lapsed in
2014 due to failure to pay maintenance fees.

The resulting
fraudulent inducement counterclaims were pled with sufficient particularity
under Rule 9(b). They also required justifiable reliance:  

Here, the circumstances involved in the agreement show that Mr.
Holsinger had no reason to doubt the veracity of Roof Maxx’s representation
that the Product was subject to a valid patent. The Feazels have a long history
of starting roofing companies, and Roof Maxx (his most recent roofing company)
is a national distributor of roofing products. Mr. Holsinger, on the other
hand, is a layperson with no previous experience in the roofing industry.
Indeed, Shingle Savers alleges that Roof Maxx and the Feazels specifically
targeted individuals with no roofing or business background for the purpose of
entering into exclusive dealer agreements. Moreover, the alleged
misrepresentations concerned the nature of Roof Maxx’s own roofing Product and
were presented in official marketing material and conversations. Given Mr.
Holsinger’s relative inexperience and the formality in which the
representations were made, it was not unreasonable for Mr. Holsinger to trust
them and rely upon them when he signed the agreement.

RM argued that reliance
wasn’t justifiable because patents are a matter of public record, but the court
declined to extend real estate cases to cover this situation. “[T]he
transaction at issue here revolved around forming a dealership relationship,
and the patent representations constituted an inducement to enter the
dealership agreement. Under these facts, a person ‘is under a duty to
reasonably investigate’ only if he was ‘put on notice as to any doubt about the
truth of representation.’” Because the facts in the counterclaim didn’t suggest
that Holsinger should have known he was being deceived, “he was not obligated
to verify the patent status by independently checking the USPTO website.”

Lanham Act/ODTPA
claims: First, the court declined to hold that Rule 9(b) applied to Lanham Act
false advertising claims, which don’t require fraud.

Did RM misrepresent “the
nature, characteristics, or quality” of its product? Its Prospective Dealer
Guide represented that “Roof Maxx has worked closely with our strategic
partners … to develop an optimal formula….The product formula is patented.” In
a sales pitch:

In 2016, Roof Maxx entered into a worldwide exclusive licensing
agreement … for the rights to the patent covering the Roof Maxx product. … Click
HERE to review the patent.

In an effort to continually bring value to our Dealers and their
customers (property owners), Roof Maxx has entered into another worldwide
exclusive licensing agreement … for a new and improved Roof Maxx formulation. This
formulation is the subject of a separate patent filed in 2017
and is
currently in the final phases of testing. [patent application number]

Despite Roof Maxx’s best efforts to provide superior products
which are covered by various patents
, the business opportunity should be
evaluated on the basis of the underlying value of the Roof Maxx product, Roof
Maxx’s world-class Onboarding and Success teams and resources, national brand
recognition, and the other systems and resources provided to the Dealer as part
of the Roof Maxx opportunity.

However, RM petitioned
the PTO to accept a late payment of the maintenance fee and was rejected, and
thus was allegedly “keenly aware” that the original patent lapsed at the end of
2014, and the PTO rejected the patent application for this second-generation
Product numerous times.

The court thought that
patent status was part of the covered “nature, characteristics,
qualities, or geographic origin” of the product. Dastar doesn’t exclude
coverage. The defendant in Dastar was in fact the origin of the products
it sold, so there was no misrepresentation of origin. Thus, the Lanham Act does
not protect a company against a rival that “steal[s] its product ideas to
manufacture a rival, facsimile product,” but Dastar didn’t cover “misrepresentations
that its Product was subject to an active, valid patent,” which weren’t the
same thing as claims about who originated or authored a product. Filing for a
patent isn’t a Lanham Act-covered act, but falsely representing patent coverage
“on marketing materials and in meetings with prospective dealers” is.
This allegedly created the impression that RM was the exclusive source of the
product and that exclusive dealers would face little or no direct competition. “As
such, these statements go directly to the Products’ nature, characteristics,
and qualities.” More generally, Section 43(a) of the Lanham Act “does reach a
seller who, by exaggerating the scope of a patent, creates a false impression
that he is the exclusive source of the product.”

Was this commercial
advertising or promotion? RM argued that it wasn’t in competition with Lexmark,
but most of the cases it cited preceded Lexmark, which removed any
competition requirement, and the others failed to grapple with Lexmark. Without
discussing whether Shingle Savers should be treated as a customer of RM—who is
not within the Lanham Act’s zone of interests—the court found that Shingle
Savers sufficiently pled “damages to its commercial interest in sales and
business reputation.” Individual RM officers were also sufficiently alleged to
be personally liable given that they allegedly were aware that the patent
lapsed and participated in making the challenged marketing materials.
 

Roof Maxx Technol., LLC
v. Tabbert,
2021 WL 3617158, No. 2:20-cv-03156
(S.D. Ohio Aug. 16, 2021); Roof Maxx Technol., LLC v. Rourk, 2021 WL 3617154,
No. 2:20-cv-03151 (S.D. Ohio Aug. 16, 2021)

In addition to the claims discussed above, defendants/counterclaimants
also alleged that RM breached the parties’ agreement by publishing disparaging
statements. The agreement said, inter alia:

The parties jointly
agree to not post for public consumption, any disparaging remarks, comments,
accounts, or other relationship detail.
Such disagreements shall be
first submitted to a licensed Mediator/Arbitrator for informal
adjudication….Any violation of this paragraph is a material breach, and
breaching party will remove, caused to be removed, or authorize removal, of
such offending public statements.

RM told a group of RM
Certified Dealers:

Recently, there have been some questions regarding why certain
Roof Maxx dealers terminated their dealerships. Roof Maxx and these dealers
have disagreements regarding various practical and legal matters pertaining to
those dealerships and their related activities.

Roof Maxx and those dealers engaged in good faith attempts to
informally resolve these issues. Initial discussions failed to resolve the matter.
In the meantime, Roof Maxx has filed lawsuits in Franklin County, Ohio,
pursuant to the terms of the respective EDAs, to have these matters adjudicated
according to law.

Roof Maxx has filed these actions to preserve the integrity of the
industry and brand that all our dedicated dealers have built (and continue to
build), as well as ensure that the time, dedication, and resources that you
have committed your success to are not diluted….

Roof Maxx respects the legal process and will not comment on or discuss
pending litigation.

The counterclaimants
argued that this amounted to an assertion that they were a threat to the integrity
of the industry and brand. [I find this statement innocuous, unlike the other
alleged activity.] The court disagreed: it didn’t specify them as one of the
dealers, and thus didn’t disclose details in contravention of the agreement.

from Blogger https://ift.tt/3y2t8La

Posted in Uncategorized | Tagged , , | Leave a comment

Even a default can’t make false claims made to Amazon violate the Lanham Act

Wilco Trading LLC v. Shabat, 2021 WL 1146634, No.
8:20-cv-579-TPB-JSS (M.D. Fla. Mar. 8, 2021) (R&R)

Wilco is an online reseller, primarily on Amazon. It allegedly
sold authentic beauty products made or branded by defendant EL Sales, which
nonetheless filed complaints on Amazon claiming that Wilco was selling
counterfeit products, and also posted a warning on the webpage for the product warning
against purchasing “counterfeits” and telling consumers only to buy from the
authorized account. Amazon suspended Wilco as a result of the complaints, and
refused to reinstate it for several months.

Defendants defaulted. Despite this, the magistrate found
that there was no valid Lanham Act claim. False complaints to Amazon weren’t “commercial
advertising or promotion.”  

Defendants’ warning on their website regarding “unauthorized
dealers” arguably was “commercial advertising” under the Lanham Act. Wilco
alleged that the warning falsely stated “that all other products are not only
‘unauthorized,” but ‘counterfeit’ and therefore dangerous.” But the complaint
didn’t identify any literally false allegations that the products could only
be found through authorized dealers. The warning would only be literally false
if no unauthorized dealers sold counterfeit Predire Paris products, and
the complaint didn’t so allege. Thus, Wilco was required to offer some evidence
of consumer deception. Even with the default, it wasn’t enough to allege that
the website was “likely to deceive and confuse the public.” Nor did it
adequately allege materiality; its claims of injury also focused on the Amazon
suspension.

FDUTPA: Doesn’t allow for consequential damages, including
lost profits, so that went too.

Tortious interference and defamation per se (false
accusations of selling counterfeits) did work, though, resulting in damages over
$166,000 but no injunction or attorney’s fees.

from Blogger https://ift.tt/3AX1zVq

Posted in Uncategorized | Tagged , | Leave a comment

claims that “infant” formula misleadingly implies special formulation survives

Youngblood v. CVS Pharmacy, 2020 WL 8991698, No. 20-cv-06251-MCS-MRW
(C.D. Cal. Oct. 15, 2020)

Youngblood bought an acetaminophen product for infants,
believing based on its packaging that it was specifically formulated for
infants and therefore different from CVS’s acetaminophen product for children.
The word “infants,” photo of a mother and infant, and instruction to “Compare
to the active ingredients in Infants’ Tylenol Oral Suspension” allegedly drove
that belief. Comparing it to the Children’s product would allegedly reinforce
that belief, because the children’s product displays an image of a parent
holding what appears to be an older child and states that it is “For Ages 2 to
11.” However, they are both dosed at 160 mg/5 mL. The formulations are identical;
the only difference is that the Infant Product comes with a syringe while the
Children’s Product comes with a plastic cup. But the Infant product costs $6.49
per ounce of medicine and the Children’s Product costs $8.79 per eight ounces
of medicine. Plaintiffs brought the usual California statutory claims.

Children’s Version

Infant Version

Although the consumer protection statutes don’t authorize
the court to set retail prices, that’s not what the complaint did. Plaintiffs
didn’t contend that the price was the source of the deception, but relied on:
(1) the name “Infants’ Pain + Fever”; (2) the instruction to “Compare to active
ingredients in Infants’ Tylenol Oral Suspension”; and (3) the picture of what
appears to be a mother holding a young child relative to the older child
featured on the Children’s Product. Without any express disclosure that the medicine
in the bottle is exactly the same, and provided at the exact same
concentration, this could plausibly lead a significant portion of the general
consuming public to concluded that the product was unique or specially
formulated for children under two. Merely displaying the acetaminophen
concentration on each package, or including a syringe in the box, didn’t foreclose
all reasonable inferences that the medicine is specially made for infants. Even
if the box had no literal untruths, a reasonable juror could nevertheless
conclude that it is “has a capacity, likelihood or tendency to deceive or
confuse the public.’ ”

from Blogger https://ift.tt/3xVEjFm

Posted in Uncategorized | Tagged , , | Leave a comment

43(a)(1)(A) claims are hard to win against a TM registrant

Zamfir v. CasperLabs, LLC, 2021 WL 1164985, No. 21cv474-GPC(AHG)
(S.D. Cal. Mar. 26, 2021)

Zamfir is a researcher in the field of cryptoeconomics and
distributed systems; he and Vitalik Buterin are allegedly the two lead
researchers of the proof-of-stake blockchain protocols known as Casper (name adopted
around 2015). Zamfir’s branch of this research, carried out in the US, became
known as “CBC Casper,” aka “Casper.”

CasperLabs was founded in October 2018 under that name. The
parties soon discussed collaborating on the research and development of a new
blockchain adopting a version of Plaintiff’s CBC Casper PoS protocol. Though
they entered into a limited agreement, Zamfir alleged that that soon after he
began working with CasperLabs, he became concerned that it was misappropriating
his name and leveraging his reputation to mislead investors. Their agreements
terminated in late 2019.

By August 2020, CasperLabs had begun referring to its
blockchain protocol and forthcoming token as “Casper.” According to CasperLabs,
Zamfir was well-aware of its intent to use the Casper name as early as June
2019. It filed an application to register CASPER as a trademark in connection
with blockchain technology; the registration issued in November 2020. Zamfir
alleged that CasperLabs had agreed to register the marks on his behalf and to
transfer the marks to him, but didn’t do so; CasperLabs denied any such agreement.
Zamfir alleged that the resulting confusion harmed his reputation, made it more
difficult to market the genuine products of his research, and gave the false
impression that his research is being financed by a relationship with CasperLabs,
which made it harder for him to secure sponsorship. CasperLabs, meanwhile, alleged
that “Casper” and “CasperLabs” had become widely recognized on social media to
refer to its network.

Without assessing whether Zamfir owned any valid interest, reasoning
that ownership of a valid mark is not a requirement under §43(a), the court jumped
straight to the Sleekcraft factors. [This is the worst of both worlds
from an unfair competition perspective: plaintiffs neither have to show that they
have a mark nor are they bound by the extra proof requirements that used to
apply for unfair competition claims, like intent and real harm.]

(1) The marks were identical. (2) Though they didn’t compete,
the marks were both used in connection with blockchain tech and “the fact that
Defendant’s product purportedly built on the CBC Casper protocol confirms that
consumers may see the ‘products’—Plaintiff’s research and Defendant’s token and
network—as related.” (3) Actual confusion: Zamfir submitted evidence from an
online forum and a newspaper article “suggesting that some in the blockchain
community mistakenly believe he is associated with Defendant’s network and
token launch.” But some of that confusion might stem from the fact that he was
associated with it in the past.

(4) Strength: Casper is conceptually strong, but Zamfir didn’t
clearly show “either that he has used the mark in a commercial manner, or that the
mark is strongly associated with him among potential cryptocurrency consumers,
which may be broader than those who are familiar with the underlying
technology.”

(5) Intent: could go either way. Though it apparently chose Casper
to suggest association with the CBC Casper protocol, it used that name throughout
its working relationship with Zamfir without objection and “it is difficult for
the Court to conclude, based on the sparse record regarding the purported
agreement, that Defendant agreed to transfer the trademark to Plaintiff without
any expectation that it would retain any right to use the Casper name at all.”

So Zamfir didn’t show likely success on the merits.

Then and only then, somewhat puzzlingly, the court proceeded
to analyze whether Zamfir had a protectable interest; he didn’t need to use a
mark in US commerce to bring a §43(a) claim, following Belmora, but he
might not be able to prevail if CasperLabs had a valid registration. The
registration was prima facie evidence of the registrant’s right to use the
mark, and “a party using a mark that they are lawfully permitted to use cannot
make a false designation by using that mark in a permitted manner.” Thus, to
prevail, Zamfir would need to rebut the presumptions created by the
registration, and he didn’t.

At the very least, the existence of the registration “would
factor into the likelihood of confusion” by “weaken[ing] the commercial
strength of the mark in connection to Plaintiff” [what] and complicating the
question of intent.

“Ultimately, given the Lanham Act’s intent to provide some
modest protections to holders of registered trademarks, the Court finds that
Plaintiff would only be likely to succeed on his false designation of origin
claim were he to overcome Defendant’s prima facie evidence that it has the
right to use the mark, whether by showing that the mark was fraudulently
registered, that Plaintiff is the owner of the mark, or otherwise demonstrating
the trademark registration is invalid or that Defendant lacks the right to use
the trademark.”

Without likely success on the merits, Zamfir wasn’t entitled
to a presumption of irreparable harm, and he couldn’t show such harm using the
sliding scale approach that applies when there are “serious questions” on the
merits (to which Herb Reed still applies even after the TMA). “A
plaintiff must present case-specific evidence of irreparable harm, rather than
relying on generic factors that are present whenever a trademark is infringed.”
Comments indicating confusion did little to “demonstrate any actual or
threatened damage to his business reputation, difficulty marketing the products
of his research, or difficulty securing sponsoring for his research.” Given the
duration of the use, he should have been able to come up with some extrinsic
evidence if it existed. “Although the question is close [why?], the Court is
doubtful that Plaintiff’s declaration alone, generally alluding to potential
reputational effects, suffices to establish that he will experience irreparable
harm absent an injunction.” Plus, he delayed seeking an injunction until less
than a week before the network launch and its token sale were set to begin, even
though he knew about it for at least seven months.

from Blogger https://ift.tt/2UBXere

Posted in Uncategorized | Tagged | Leave a comment

D’s own ads prove materiality of difference between Fraser and balsam firs

Evergreen East Cooperative v. Bottomley Evergreens &
Farms, Inc., 2021 WL 1163799, No. 20-cv-184 (AJN) (S.D.N.Y. Mar. 26, 2021)

“Christmas tree distributor Evergreen East Cooperative claims
that its rival Bottomley Evergreens & Farms sold mislabeled trees through
retail partners including Home Depot and Whole Foods.” Defendants moved to
dismiss, relevantly arguing that consumers would not care whether their trees
were the more desirable Fraser firs (as advertised) or cheaper, faster-drying, more-shedding
balsam firs (as they were in fact). Defendant Whole Foods wasn’t adequately
alleged to be liable, but the other claims survived.

Evergreen allegedly paid more for Fraser firs because of
their scarcity, and so was forced to market them to consumers for higher
prices. Bottomley allegedly imported thousands of balsam firs from Canada,
labeled them as Fraser firs, and sold them to consumers throughout the New York
area, undercutting Evergreen’s prices for genuine Fraser firs and making
consumers believe that its prices were unreasonable.

The labels at Home Depot used the words “Fraser Fir” printed
in large letters, followed by three bullet points: “Most highly awarded
Christmas tree”; “Superior needle retention with sturdy branches for
ornaments”; “Soft texture and traditional holiday fragrance.” Home Depot’s
in-store signage and advertising also identified the trees as Fraser firs. Evergreen
notified Home Depot of the problem, but it took no action for the rest of the
Christmas season. However, it didn’t allege that Whole Foods used misleading
labels or that it notified Whole Foods of the problem.

Materiality: “Accepting Evergreen’s allegations as true and
drawing all reasonable inferences in its favor, there are significant
differences between balsam and Fraser firs that affect their desirability to
consumers and drive the Fraser fir’s higher price…. Bottomley and Home Depot
offer no argument as to why shorter shelf life and inferior durability would
not influence the purchasing decisions of consumers.” Instead, they argued that
shoppers examine individual trees, so they’d pick the one they wanted
aesthetically. Even if that were appropriate on a motion to dismiss, “[a]s
between two trees that look the same, consumers might prefer (and pay more for)
one that will retain its needles longer.”

Plus, their own advertising also refuted their immateriality
argument.

The trees’ labels prominently
identify them as Fraser firs—twice on just the front of the label. The label
then lists qualities of Fraser firs as selling points to consumers. In
isolation, a statement like “superior needle retention” might amount to no more
than puffery. But the label does not present this claim as a vague boast about
the quality of the seller’s trees. Instead, it lists it as a bullet point
beneath the heading “Fraser Fir” along with other statements that appear to
describe that variety of tree, conveying the message that consumers should
select Fraser firs over other Christmas trees because of their particular
qualities. Puffery or not, the label reflects that consumers should—and do—care
about the difference between Fraser firs and balsam firs.

As for causation, this was “the classic Lanham Act
false-advertising claim in which one competitor directly injures another by
making false statements about his own goods or the competitor’s goods and thus
inducing customers to switch.” “This Court disagrees with Bottomley and Home
Depot that a plaintiff needs to plead an encyclopedic set of details about the
Christmas tree market, their inventory, and the characteristics of their trees to
plausibly allege causation under this well established theory.”

State claims: Was this consumer-oriented conduct or merely
private harm? § 349 doesn’t require harm to public safety. “Where the allegedly
deceptive communication is made directly to consumers, it is self-explanatory
that the conduct is ‘consumer-oriented,’ and thus no further showing on this
element is required.” Also, “consumers are harmed when they do not get what
they pay for.” Contrary district court holdings were “plainly inconsistent with
subsequent pronouncements of the New York Court of Appeals.”

from Blogger https://ift.tt/3xZapA8

Posted in Uncategorized | Tagged | Leave a comment

TM question of the day: This Ain’t Goya spice blend

 This Ain’t Goya spice blend.

Suppose the makers sought registration for this as a trademark for spice blends. Would prohibiting registration violate the First Amendment?

from Blogger https://ift.tt/2XEU0Er

Posted in Uncategorized | Tagged | Leave a comment

Overreaching and delay lead to defeat of TM owner’s claims

Sturgis Motorcycle Rally, Inc. v. Rushmore Photo &
Gifts, Inc., 2021 WL 1176242, No. CIV. 11-5052-JLV (D.S.D. Mar. 29, 2021)

This is part of a long-running trademark case, now over 10
years old. After a jury verdict for SMRI and a partial reversal thereof by the
court of appeals, the status is this: STURGIS and STURGIS MOTORCYCLE RALLY for
motorcycle rallies (etc.) were invalid; defendants didn’t infringe on TAKE THE
RIDE TO STURGIS mark; STURGIS BIKE WEEK and BLACK HILLS MOTOR CLASSIC STURGIS
RALLY & RACES BLACK HILLS S.D. were valid and infringed, but the latter
wasn’t counterfeited; SMRI’s dilution victory was vacated, but not its victories
on deceptive trade practices, ACPA, false advertising, and unfair competition.

Here the court considers acquiescence and laches. For
example (the details vary a little depending on defendant, but you get the
picture): The STURGIS BIKE WEEK registration dates to 1997; defendants’ “Sturgis
Motor Classic” came from 1997-98. SMRI’s predecessor in interest did business
with the relevant defendants from at least 1999-2009; resold products bearing “Sturgis
Motor Classic” in its own retail store; and never complained about the use of
“Sturgis” or “Sturgis Motor Classic” on rally products. During this period,
defendants continued to grow and develop their inventory and marketed “Sturgis”
and “Sturgis Motor Classic” rally products. SMRI ultimately sent one C&D in
August 2006, and filed suit in June 2011.

One defendant’s principal testified that it “specifically
tried very hard to differentiate” its products with a disclaimer expressly
disavowing any affiliation with SMRI and a separate color scheme on its tags,
which SMRI copied. After the complaint was filed, that defendant permitted its
state trademark applications and domain name registrations to lapse and
abandoned its federal trademark application for “Sturgis Motorcycle Classic.” It
also stopped using “Officially Licensed Sturgis,” “Licensed Sturgis,” and
“Authentic Sturgis.”  

Acquiescence requires (1) knowledge by SMRI or its
predecessors in interest of the defendant’s use; (2) implied or express consent
to that use; (3) defendant’s change in position in reliance on that conduct.

Since the jury made no relevant findings of fact, the court
was free to make findings. It doesn’t start well for SMRI:

While the 2006 cease and desist
letter’s statement [that SMRI had a registered mark] was true as it relates to
the Composite Design Mark [the long one above + design], SMRI’s suggestion that
registration for STURGIS had been approved was not true and was deceptive. … The
Composite Design Mark registration specifically acknowledged that it made “no
claim … to the exclusive right to use ‘MOTOR CLASSIC’ or ‘RALLY & RACES
BLACK HILLS S.D.’ apart from the mark as shown.”

Also:

It is incomprehensible that for
over 10 years no one at [the predecessor] would have knowledge of these rally
products being purchased at wholesale from [defendant] RP&G and then being
resold at retail in its own store. By purchasing “Sturgis” and “Sturgis Motor
Classic” items from RP&G and then reselling them through its own retail
locations, [the predecessor] expressly or impliedly represented that it would
not assert a right or exclusive claim to use those terms.

Even after the first transfer, to the Sturgis Chamber of
Commerce, the Chamber did the same thing back into the 1990s, buying these
products and reselling them at its own store. There was acquiescence, and the
defendants changed their position in reliance on it by continuing to build
their Sturgis product line, which they likely wouldn’t have done had SMRI or
its predecessors acted earlier, as they showed by scaling back various
activities when the suit began.

Laches: This is about passive consent, not active consent as
with acquiescence. It requires inexcusable delay and prejudice. The laches
defense is not available “when the defendant knew that the plaintiff objected
to the use of the mark,” as “[a]ny acts after receiving a cease and desist
letter are at the defendant’s own risk.” Also: “When a defendant has invested
generally in an industry, and not a particular product, the likelihood of
prejudicial reliance decreases in proportion to the particular product’s role
in the business.”

This is basically the same; SMRI didn’t explain why it
waited 4 years and 10 months to sue. Even after the C&D, the RP&G defendants
continued to sell “Sturgis” rally products in the good-faith belief that the
term “Sturgis” was generic, a belief validated by the Eighth Circuit’s
endorsement. It expanded its employee workforce and invested millions of
dollars in its Sturgis-related rally products. Thus, defendants also established
laches.

Laches also applied to the state law deceptive trade
practices claim.

What about unclean hands? The RP&G defendants “willfully
and intentionally infringed the Composite Design mark” on a single product, a
shot glass. But, “the differences between the glass’s design and the [SMRI]
mark are so obvious,” the Eighth Circuit ruled “the jury did not have any basis
in the record [to support a] finding [the shot glass was] a counterfeit.” When
the RP&G Defendants used “Sturgis” and “STURGIS MOTOR CLASSIC,” they did so
“in the face of [SMRI’s] disputed title” and they did so in good faith. They
used their own labels and tags to differentiate their products, and disclaimed
affiliation with SMRI. Thus, “[t]he record … fails to reveal the subjective
and knowing bad faith necessary to foreclose the equitable defenses.” Even if
they did have unclean hands, it wasn’t particularly egregious and the court
would decline to apply the doctrine.

Wal-Mart, which carried RP&G products, was also not a
willful infringer. The first year it carried them, a manager observed the
RP&G Defendants’ tags disclaiming any relationship with SMRI but
proclaiming the products to be “official Sturgis Motorcycle Rally products.” The
manager called SMRI’s licensing agent and learned the RP&G products were
not officially licensed by SMRI. “While this may have been bad business
judgment on the part of Wal-Mart, the conduct does not rise to the level of ‘subjective
… bad faith,’ or ‘particularly egregious conduct.”

What about SMRI’s own conduct? In 2001, an examiner rejected
the Sturgis Chamber’s attempt to register STURGIS as primarily geographically
descriptive. The Chamber fought back, and there were oppositions by other local
motorcycle/rally-related users. SMRI, as successor, eventually bought two major
opponents off. “In exchange for Sturgis Motorcycle’s withdrawal of its
opposition to the Chamber’s original TM application, SMRI agreed Sturgis
Motorcycle could use the STURGIS mark without any licensing agreement with
either the Chamber or SMRI. Another company owner agreed to dismiss his company’s
opposition and become the exclusive licensee of SMRI’s trademarks, while he
became a member of SMRI’s board of directors.  Its application was then successful.

The jury, applying a clear and convincing evidence standard,
concluded SMRI had not obtained the STURGIS trademark registration
fraudulently. But the Eighth Circuit said:

The only way that [the Chamber’s
declarant] Martin was able to assert that the Chamber had substantially
exclusively used the word “Sturgis” for decades to promote the rally was by
denying that virtually anyone else promoted it when they independently used the
word to sell their own rally-related goods and services…. Although it was
patently unreasonable for Martin to think that only Chamber-approved uses of
the mark counted as rally-related uses, it was this logic that enabled him to
tell the Trademark Office that the word “Sturgis” had become distinctive
through the Chamber’s substantially exclusive use of it in connection with the
marketing and promotion of the rally.

Martin’s logic was so incoherent
and self-serving that no reasonable jury could accept it…. The fact that
non-Chamber-affiliated producers were using the word [“Sturgis”] on their
rally-related products was directly relevant to whether the Chamber was its
substantially exclusive user. Martin, however, ignored those third-party uses
since he believed that only the Chamber actually promoted the rally. But he had
no right to declare that by fiat…. It is irrelevant to our conclusion here
that the jury also found that Martin did not “knowingly” lie in his affidavit:
A person can be indisputably, but sincerely, wrong.

Despite the Eighth Circuit’s holding that the STURGIS mark
was invalid, “SMRI continues to irrationally assert its STURGIS marks are valid,”
including in PTO proceedings. The trial court’s cancellation order was not an
interlocutory decision, as SMRI told the PTO it was. Nonetheless, through the
August 2020 rally and beyond, SMRI continued to hold itself out as the owner of
“Sturgis®,” “Sturgis® Motorcycle Rally™,” and “Sturgis Rally & Races™.” It
continued to sell STURGIS® products. “SMRI’s website intimidates or at least
impliedly intimidates Sturgis Rally venders to ‘Apply to Become a Sturgis®
Licensee.” This was a continuing “calculated attempt to confuse … the public
about the STURGIS Registrations.” Courts don’t like defiance! “[T]hose three
marks were invalided by the Eighth Circuit in 2018. The public has an interest
in respect for court orders and a ‘right not to be deceived or confused’ by
SMRI’s misrepresentations about its marks.”

SMRI had unclean hands. It was thus barred from equitable
relief for its trademark infringement, false advertising, and state deceptive
trade practices claims.

Separately, the court considered whether various other
defendants could assert acquiescence and laches, and found that they could. Money
judgments against them were vacated.

from Blogger https://ift.tt/2W7ErET

Posted in Uncategorized | Tagged , , | Leave a comment

industry group’s safety/risk/legality claims were plausibly false or misleading

Pharmacychecker.Com, LLC v. National Ass’n of Boards of
Pharmacy, 2021 WL 1199363, — F. Supp. 3d –, No. 19-CV-7577 (KMK) (S.D.N.Y. Mar.
30, 2021)

Plaintiff “offers an accreditation program for pharmacies and
provides drug price comparison information.” Unlike its competitors, it does
this for pharmacies worldwide and US online pharmacies. It does not itself sell
or import prescription drugs, but personal imports may sometimes be permitted. It
 alleged that defendants unlawfully
conspired to restrain trade in violation of the Sherman Act and that NABP engaged
in false advertising in violation of the Lanham Act.

NABP is an association of state boards of pharmacy and
competes with plaintiff in the pharmacy accreditation market through its
Verified Internet Pharmacy Practice Sites (VIPPS) program, its “.pharmacy”
Verified Websites program, and its Internet Drug Outlet Identification Program.
The other defendants allegedly competed in various ways and coordinated to shut
plaintiff out of the market, including by getting Bing to show users “a red
caution shield and a warning box when clicking on search results for pages from
Plaintiff’s website and blog, causing Plaintiff to lose 76% of its web traffic
from Bing.” I will not address the antitrust claims.

Lanham Act claims against NABP:  “NABP’s website claims that sites on its Not
Recommended List are unsafe and illegal, including Plaintiff’s website and
blog.” This is allegedly false or misleading.

Safety and risk statements: NABP says (1) that its Not
Recommended Sites list “includes websites that ‘are known to be unsafe’ or that
‘may: Dispense prescription medicine without a prescription; Dispense foreign
or unapproved medicine; or Refer/link patients to sites that facilitate the
dispensing of prescription medications in violation of state or federal law or
NABP standards.’ ” (2) “[o]rdering drugs from these websites put you and your
family at risk.” (3) “[t]he following sites are all known to be unsafe.” (4)
“[u]sing websites on the NRL to purchase drugs may put you or your loved ones
at risk.”

Though courts are divided on whether safety/risk statements
are opinion, “serious” safety concerns may be more than opinion if they are “expressing
an objective risk of serious consequences that fairly implies a basis for that
statement.” So here: these statements “appear to have a factual basis” by
saying, e.g., that the sites on the NRL are “known to be unsafe.” Plaintiff also
plausibly alleged misleadingness.

Illegality: The relevant statements were (1) “ ‘[a]void
[t]hese [w]ebsites’ [on the Not Recommended Sites list] because they ‘appear to
be out of compliance with state and federal laws or NABP patient safety and
pharmacy practice standards.’ ” (2) “websites on the list … are ‘acting
illegally or do not follow best practices.’ ” “Since both statements are
disjunctive, if one element of each statement is true, they cannot be literally
false.” However, plaintiff didn’t allege that the statements were literally
false as to best practices for one of its sites (PharmacyChecker.com). But it
did plausibly allege that “NABP’s statements about PharmacyCheckerBlog.com are
literally false, because it is a policy advocacy blog that does not even
arguably meet any criteria that NABP lists on the Not Recommended Sites list.” Conflating
plaintiff with illegal sites was plausibly misleading, especially as NABP
allegedly earlier said of plaintiff: “clearly they serve a purpose, and they
help consumers, and we serve a different purpose, or maybe just slightly
different.” This inconsistency justified a plausible inference of deliberate
deception. Indeed, it was plausible that this was egregious conduct, since “the
record does not suggest that such deception is common in the industry.”

Was this sufficiently alleged to be commercial speech? Yes. First,
NABP’s statements were plausibly ads, in that they included “Buy safely” with a
link to a list of NABP affiliates. Second, they therefore referred to specific
products. Third, plaintiff alleged that competition with it in the market for
pharmacy accreditation provided an economic motivation for NABP’s speech.
Plaintiff was not required to allege that NABP’s speech led to a specific
transaction.

from Blogger https://ift.tt/3yXPuyJ

Posted in Uncategorized | Tagged , | Leave a comment

Vegan butter wins again

Miyoko’s Kitchen v. Ross, No. 20-cv-00893-RS (N.D. Cal. Aug.
10, 2021)

Preliminary
injunction discussed here;
now it’s summary judgment time. The state is
allowed to regulate “hormone free” on Miyoko’s “vegan butter,” but Miyoko’s is
allowed to use the words/phrases “butter,” “lactose free,” “cruelty free,” and
“revolutionizing dairy with plants.” The state’s initial attempt to regulate
Miyoko’s website (which had images of cows), not just its label, was concededly
beyond its statutory authority and now that part of the case is moot.

front of European Style Cultured Vegan Butter from Miyoko’s Creamery

side: the Hormone Free claim must go

back: “revolutionizing dairy with plants”

The key piece of evidence was a 2018 study by Silke Feltz
and Adam Feltz, “Consumer Accuracy at Identifying Plant-based and Dairy-based
Milk Items.” It didn’t involve “vegan butter,” but studied what happened when
producers combined dairy signifiers (e.g., “cheese” and “milk”) with dairy-disclaiming
language (e.g., “dairy free”). It indicates, in relevant part, that the public
“accurately identifie[s] the source of animal-based milk products 84% of the
time, plant-based milk-products 88% of the time, animal-based cheese products
81% of the time, and plant-based cheese products 74% of the time.”

This study could not justify the “heavy” burden imposed by Central
Hudson
on the state’s attempt to bar the use of these terms (except for “hormone
free”).

Hormone free: Miyoko’s “vegan butter” product contains
naturally occurring plant hormones;

“hormone free” is thus irrefutably false.

This was the state’s only victory.

It’s true that federal dairy and fat-content requirements
for “butter” exclude Miyoko’s “vegan butter.” But Central Hudson doesn’t
protect “only what the government leaves undefined.” Even the fact that this
definition had been unchallenged for 90 years wasn’t important; the court didn’t
agree that it was therefore “especially reflective of what consumers understand
‘butter’ to mean.” Indeed, the court thought that it defied “common sense” to
think that consumers’ understanding of “butter” had been shaped by 90 years of
seeing the term on its own applied only to dairy products. The state was required
to provide “more faithful indicators of present-day linguistic norms,” and it
didn’t.

The Feltz study didn’t help either. True, a confusion rate
of 26% for plant-based cheese products was “solid evidence” that using a dairy
product name/dairy-associated statements on a dairy-alternative product could be
confusing. But 19% were also confused by animal-based cheeses. This modest
difference didn’t suffice to make “vegan butter” inherently misleading.

Footnote of interest to TM folks: The state argued that,
because “the Lanham Act is constitutional,” and because “a handful” of federal
trademark plaintiffs have secured injunctions with “survey results where 15% of
customers” expressed confusion, the Feltz study should be given strong
pro-state weight. But those cases provided no justification for assigning “strong
First Amendment significance” to the Feltz’s study’s 26% result (especially
given that a 15% threshold would “bode ill for ‘milk’ and ‘cheese’ when used to
market dairy products”). [I do note that the concept of “net” confusion might
help everyone here. Also: the day is coming when courts in TM cases will note
that they have not really done Central Hudson balancing like this, especially
when they are dealing with low but nonzero net confusion results.]

Nor did the state show that is regulation served a
substantial interest in avoiding customer confusion. And having a “consistent
scheme” for the regulation of food labeling wasn’t enough of an interest, at
least at this level of generality. “[T]he First Amendment demands proof that
restricting Miyoko’s commercial speech will promote the State’s asserted
interest.” Result: Sure, you can have standards of identity for food … as long
as no one in the industry challenges them.

from Blogger https://ift.tt/3yXnivN

Posted in Uncategorized | Tagged , , | Leave a comment